$1,000-per-pill drug overtaken by pricier successor

Jul 11, 2015

The $1,000 pill for a liver-wasting viral infection that made headlines last year is no longer the favorite of patients and doctors. The new leading pill for hepatitis C is more expensive, and the number of patients seeking a cure has surged. Read More

CalPERS approves 7.2% increase in HMO rates as drug costs climb

Jun 18, 2015

CalPERS said it spent nearly $40 million for Sovaldi on plans run by Blue Shield of California, Kaiser Permanente and CVS Health. Read More

ICYMI: “Prescription drug prices climb into the stratosphere”

May 20, 2015

May 20, 2015 “Prescription drug prices climb into the stratosphere” Read More

New Drug Report Confirms Drug Prices On Unsustainable Path

Mar 11, 2015

Reaction from National Coalition on Health Care President and CEO John Rother Read More

Justifying After the Fact Is Not Justification

Oct 22, 2014

What the study should have asked is whether or not the price Gilead set for the therapy is appropriate for all patients–even asymptomatic patients–and whether or not such a large portion of potential societal value should accrue to one company. Read More

[The Morning Consult] The Gilead Effect

Oct 14, 2014

Perhaps no company has done as much as Gilead to propel the issue of high drug prices onto center stage or to lay bare the pharmaceutical industry’s approach to pricing new drugs. Read More

[WSJ] Will ‘Son of Sovaldi’ Cause State Medicaid Programs to Erect High Hurdles?

Oct 13, 2014

How might state Medicaid programs cope with a new and equally expensive hepatitis C treatment from Gilead Sciences. Read More

[The Wall Street Journal] France Will use Taxes to Pressure Drug Makers on Hep C Prices

Sep 30, 2014

In an effort to blunt the high price of hepatitis C treatments Read More

[The Washington Post] The new $84,000 hepatitis C treatment is losing momentum, for now

Sep 18, 2014

After recording the best launch of any drug in history, it looks like the pace is starting to slow down for Gilead Sciences' Sovaldi — the new $84,000 hepatitis C cure that's sparking a new focus on specialty drug costs. Read More

Gilead–The Predictable Path or the Road Less Traveled?

Sep 17, 2014

Gilead should be commended for taking action to make their best-selling treatment for Hepatitis C, Sovaldi, available to more people around the world. In India, they’ve struck licensing agreements with generic firms to produce the product for pennies on the dollar. Unfortunately, Gilead’s largess is being funded largely on the backs of American families. Read More

[Reuters] Study shows downward trend in Sovaldi utilization

Sep 17, 2014

Over the last several months there has been a 'plateau and downward trend' in the use of Gilead Sciences Inc's controversial $1,000-a-pill hepatitis C treatment, Sovaldi, a CVS Health Corp analysis showed. Read More